New JAK Inhibitor for Rheumatoid Arthritis Hits Targets New JAK Inhibitor for Rheumatoid Arthritis Hits Targets

Filgotinib is effective and well tolerated by patients with moderate to severe rheumatoid arthritis, early phase 3 results show, and investigators speculate it will enter the market in about 2 years.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Source Type: news